289 related articles for article (PubMed ID: 26244699)
21. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.
Bonaventure J; Horne WC; Baron R
FEBS J; 2007 Jun; 274(12):3078-93. PubMed ID: 17509076
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications.
Iwamoto T; You M; Li E; Spangler J; Tomich JM; Hristova K
Biochim Biophys Acta; 2005 Mar; 1668(2):240-7. PubMed ID: 15737335
[TBL] [Abstract][Full Text] [Related]
23. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.
Tavormina PL; Bellus GA; Webster MK; Bamshad MJ; Fraley AE; McIntosh I; Szabo J; Jiang W; Jabs EW; Wilcox WR; Wasmuth JJ; Donoghue DJ; Thompson LM; Francomano CA
Am J Hum Genet; 1999 Mar; 64(3):722-31. PubMed ID: 10053006
[TBL] [Abstract][Full Text] [Related]
24. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans.
Vajo Z; Francomano CA; Wilkin DJ
Endocr Rev; 2000 Feb; 21(1):23-39. PubMed ID: 10696568
[TBL] [Abstract][Full Text] [Related]
25. Mild achondroplasia/hypochondroplasia with acanthosis nigricans, normal development, and a p.Ser348Cys FGFR3 mutation.
Couser NL; Pande CK; Turcott CM; Spector EB; Aylsworth AS; Powell CM
Am J Med Genet A; 2017 Apr; 173(4):1097-1101. PubMed ID: 28181399
[TBL] [Abstract][Full Text] [Related]
26. Role of dimerization efficiency of transmembrane domains in activation of fibroblast growth factor receptor 3.
Volynsky PE; Polyansky AA; Fakhrutdinova GN; Bocharov EV; Efremov RG
J Am Chem Soc; 2013 Jun; 135(22):8105-8. PubMed ID: 23679838
[TBL] [Abstract][Full Text] [Related]
27. Crouzon syndrome with acanthosis nigricans and prominent diffuse hyperpigmentation associated with gain-of-function A391E mutation in FGFR3 gene.
Kariya H; Nakano H; Ishii N; Kaimi Y; Imai K; Nakanishi Y; Kunihiro N; Fukai K
J Dermatol; 2020 Dec; 47(12):e451-e452. PubMed ID: 32860240
[No Abstract] [Full Text] [Related]
28. Measuring the energetics of membrane protein dimerization in mammalian membranes.
Chen L; Novicky L; Merzlyakov M; Hristov T; Hristova K
J Am Chem Soc; 2010 Mar; 132(10):3628-35. PubMed ID: 20158179
[TBL] [Abstract][Full Text] [Related]
29. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
Adar R; Monsonego-Ornan E; David P; Yayon A
J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
[TBL] [Abstract][Full Text] [Related]
30. A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes Crouzon syndrome and acanthosis nigricans.
Wilkes D; Rutland P; Pulleyn LJ; Reardon W; Moss C; Ellis JP; Winter RM; Malcolm S
J Med Genet; 1996 Sep; 33(9):744-8. PubMed ID: 8880573
[TBL] [Abstract][Full Text] [Related]
31. Long-term survival in typical thanatophoric dysplasia type 1.
Baker KM; Olson DS; Harding CO; Pauli RM
Am J Med Genet; 1997 Jun; 70(4):427-36. PubMed ID: 9182787
[TBL] [Abstract][Full Text] [Related]
32. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
[TBL] [Abstract][Full Text] [Related]
33. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice.
Iwata T; Li CL; Deng CX; Francomano CA
Hum Mol Genet; 2001 Jun; 10(12):1255-64. PubMed ID: 11406607
[TBL] [Abstract][Full Text] [Related]
34. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
Lievens PM; Liboi E
J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
[TBL] [Abstract][Full Text] [Related]
35. Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.
Sarabipour S; Hristova K
J Mol Biol; 2016 Oct; 428(20):3903-3910. PubMed ID: 27596331
[TBL] [Abstract][Full Text] [Related]
36. Primary and secondary dimer interfaces of the fibroblast growth factor receptor 3 transmembrane domain: characterization via multiscale molecular dynamics simulations.
Reddy T; Manrique S; Buyan A; Hall BA; Chetwynd A; Sansom MS
Biochemistry; 2014 Jan; 53(2):323-32. PubMed ID: 24397339
[TBL] [Abstract][Full Text] [Related]
37. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.
Jin M; Yu Y; Qi H; Xie Y; Su N; Wang X; Tan Q; Luo F; Zhu Y; Wang Q; Du X; Xian CJ; Liu P; Huang H; Shen Y; Deng CX; Chen D; Chen L
Hum Mol Genet; 2012 Dec; 21(26):5443-55. PubMed ID: 23014564
[TBL] [Abstract][Full Text] [Related]
38. Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia.
Hyland VJ; Robertson SP; Flanagan S; Savarirayan R; Roscioli T; Masel J; Hayes M; Glass IA
Am J Med Genet A; 2003 Jul; 120A(2):157-68. PubMed ID: 12833394
[TBL] [Abstract][Full Text] [Related]
39. The A391E mutation enhances FGFR3 activation in the absence of ligand.
Chen F; Degnin C; Laederich M; Horton WA; Hristova K
Biochim Biophys Acta; 2011 Aug; 1808(8):2045-50. PubMed ID: 21536014
[TBL] [Abstract][Full Text] [Related]
40. Subtle radiographic findings of achondroplasia in patients with Crouzon syndrome with acanthosis nigricans due to an Ala391Glu substitution in FGFR3.
Schweitzer DN; Graham JM; Lachman RS; Jabs EW; Okajima K; Przylepa KA; Shanske A; Chen K; Neidich JA; Wilcox WR
Am J Med Genet; 2001 Jan; 98(1):75-91. PubMed ID: 11426459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
